Amin H. Nassar

Alıntı yapanlar

	Hepsi	2020 yılından bugüne
Alıntılar	2500	2465
h-endeksi	23	23
i10-endeksi	42	42

760

380

190

570

201920202021202220232024202527 132 348 464 599 741 150

Genel erişim

Tümünü görüntüle

37 makale

1 makale

genel erişime açık olanlar

genel erişime açık olmayanlar

Finansman sağlayan kuruluşun getirdiği zorunluluğa dayalı olarak

Katkıda bulunan yazarlar

Toni ChoueiriDana-Farber Cancer Institutedfci.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Sarah Abou AlaiwiCardiology Fellow, Yale New Haven Hospitalyale.edu üzerinde doğrulanmış e-posta adresine sahip
David J. KwiatkowskiProfessor of Medicine, Harvard Medical Schoolrics.bwh.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Elio AdibHarvard Radiation Oncology Programdfci.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Pier Vitale NuzzoWeill Cornell Medicine, New York-Presbyterian Hospital, New York, USAmed.cornell.edu üzerinde doğrulanmış e-posta adresine sahip
Lauren C Harshman MDsurfaceoncology.com üzerinde doğrulanmış e-posta adresine sahip
Eliezer Van AllenDana-Farber Cancer Institutedfci.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Ziad BakounyMemorial Sloan Kettering Cancer Centermskcc.org üzerinde doğrulanmış e-posta adresine sahip
Joaquim BellmuntAssociate Professor of Medicine Harvard Medical Schooldfci.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Mark A. PrestonBrigham and Women's Hospital/Dana Farber Cancer Institutebwh.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Tarek MouhieddineIcahn School of Medicine at Mount Sinaimountsinai.org üzerinde doğrulanmış e-posta adresine sahip
Sabina SignorettiProfessor, Brigham and Women's Hospital, Harvard Medical Schoolbwh.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Alexander (Sasha) GusevDana-Farber Cancer Institutedfci.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Ronan FlippotMDgustaveroussy.fr üzerinde doğrulanmış e-posta adresine sahip
Atul ShinagareDana-Farber Cancer Institute/ Brigham and Women's hospital, Bostonpartners.org üzerinde doğrulanmış e-posta adresine sahip
Jacob E. BerchuckEmory University School of Medicineemory.edu üzerinde doğrulanmış e-posta adresine sahip
JAEGIL KIMGSKgsk.com üzerinde doğrulanmış e-posta adresine sahip
Abdallah FlaifelNational Cancer Institutenih.gov üzerinde doğrulanmış e-posta adresine sahip
Mahsa Zarei, Ph.D.bwh.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Elie W. AklBrigham and Women's Hospital

Takip et

Amin H. Nassar

Yale New Haven Hospital/Yale University

yale.edu üzerinde doğrulanmış e-posta adresine sahip

Thoracic Oncology Genetic Ancestry Genomics Epigenomics


Başlık Alıntılara göre sırala Yıla göre sırala Başlığa göre sırala	Alıntı yapanlar Alıntı yapanlar	Yıl
Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes PV Nuzzo, JE Berchuck, K Korthauer, S Spisak, AH Nassar, S Abou Alaiwi, ... Nature medicine 26 (7), 1041-1043, 2020	258	2020
Distribution of KRAS^G12C Somatic Mutations across Race, Sex, and Cancer Type AH Nassar, E Adib, DJ Kwiatkowski New England Journal of Medicine 384 (2), 185-187, 2021	176	2021
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant TH Mouhieddine, AS Sperling, R Redd, J Park, M Leventhal, CJ Gibson, ... Nature communications 11 (1), 2996, 2020	149	2020
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer SC Baca, DY Takeda, JH Seo, J Hwang, SY Ku, R Arafeh, T Arnoff, ... Nature Communications 12 (1), 1979, 2021	129	2021
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ... Nature communications 12 (1), 808, 2021	129	2021
Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites AH Nassar, R Umeton, J Kim, K Lundgren, L Harshman, EM Van Allen, ... Clinical Cancer Research 25 (8), 2458-2470, 2019	127	2019
Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021	122	2021
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors E Adib, AH Nassar, EW Akl, S Abou Alaiwi, PV Nuzzo, TH Mouhieddine, ... Clinical Cancer Research 27 (14), 4025-4035, 2021	91	2021
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors AH Nassar, E Adib, S Abou Alaiwi, T El Zarif, S Groha, EW Akl, PV Nuzzo, ... Cancer Cell 40 (10), 1161-1172. e5, 2022	83	2022
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma S Abou Alaiwi, W Xie, AH Nassar, S Dudani, D Martini, Z Bakouny, ... Journal for ImmunoTherapy of Cancer 8 (1), 2020	81	2020
Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors S Abou Alaiwi, AH Nassar, W Xie, Z Bakouny, JE Berchuck, DA Braun, ... Cancer immunology research 8 (8), 1075-1084, 2020	76*	2020
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma AH Nassar, KW Mouw, O Jegede, AB Shinagare, J Kim, CJ Liu, ... British journal of cancer 122 (4), 555-563, 2020	74	2020
Germline variants associated with toxicity to immune checkpoint blockade S Groha, SA Alaiwi, W Xu, V Naranbhai, AH Nassar, Z Bakouny, T El Zarif, ... Nature medicine 28 (12), 2584-2591, 2022	71	2022
Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma K Lasseter, AH Nassar, L Hamieh, JE Berchuck, PV Nuzzo, K Korthauer, ... Genetics in Medicine 22 (8), 1366-1373, 2020	65	2020
Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma AH Nassar, S Abou Alaiwi, SH AlDubayan, N Moore, KW Mouw, ... Genetics in Medicine 22 (4), 709-718, 2020	65	2020
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma BA McGregor, AKA Lalani, W Xie, JA Steinharter, ZE Bakouny, DJ Martini, ... European Journal of Cancer 135, 203-210, 2020	62	2020
PD-L1 expression and clinical outcomes to cabozantinib, everolimus, and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials … A Flaifel, W Xie, DA Braun, M Ficial, Z Bakouny, AH Nassar, RB Jennings, ... Clinical Cancer Research 25 (20), 6080-6088, 2019	57	2019
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology E Adib, AH Nassar, S Abou Alaiwi, S Groha, EW Akl, LM Sholl, ... Genome Medicine 14 (1), 39, 2022	55	2022
Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the cancer therapy using checkpoint inhibitors in people … T El Zarif, AH Nassar, E Adib, BG Fitzgerald, J Huang, TH Mouhieddine, ... Journal of Clinical Oncology 41 (21), 3712-3723, 2023	34	2023
CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer E Adib, T El Zarif, AH Nassar, EW Akl, S Abou Alaiwi, TH Mouhieddine, ... British journal of cancer 126 (5), 797-803, 2022	29	2022

Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.

Makaleler 1–20

Yıllık alıntı sayısı

Mükerrer alıntılar

Birleştirilmiş alıntılar

Katkıda bulunan yazar ekleKatkıda bulunan yazarlar

Takip et

Alıntı yapanlar

Katkıda bulunan yazarlar